Pembrolizumab + Lenvatinib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mesotheliomas Pleural
Conditions
Mesotheliomas Pleural
Trial Timeline
Mar 1, 2021 → Mar 5, 2026
NCT ID
NCT04287829About Pembrolizumab + Lenvatinib
Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Merck for Mesotheliomas Pleural. The current trial status is active. This product is registered under clinical trial identifier NCT04287829. Target conditions include Mesotheliomas Pleural.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07011849 | Phase 2 | Withdrawn |
| NCT06266338 | Phase 2 | Recruiting |
| NCT05545969 | Phase 2 | Withdrawn |
| NCT04865887 | Phase 2 | Recruiting |
| NCT05273554 | Phase 1 | Active |
| NCT04955743 | Phase 2 | Terminated |
| NCT05147558 | Phase 2 | Active |
| NCT05078931 | Phase 2 | Active |
| NCT04848337 | Phase 2 | Active |
| NCT04729348 | Phase 2 | Terminated |
| NCT04287829 | Phase 2 | Active |
| NCT04207086 | Phase 2 | Active |
| NCT03290079 | Phase 2 | Completed |
Competing Products
2 competing products in Mesotheliomas Pleural
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cemiplimab + Fianlimab + Pemetrexed (Alimta) + Cisplatin + Carboplatin (AUC 5) | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Ivonescimab | Summit Therapeutics | Phase 2 | 49 |